Stockpiling medicines at the onset of the COVID-19 pandemic: an empirical analysis of national prescription drug sales and prices
Files
First author draft
Date
DOI
Authors
Minje, Park
Tucker, Anita L.
Erin, R. Fox
Conti, Rena M.
Version
First author draft
OA Version
Citation
P. Minje, A. Carson, F. Erin, R. Conti. "Stockpiling Medicines at the Onset of the COVID-19 Pandemic: An Empirical Analysis of National Prescription Drug Sales and Prices." Management Science,
Abstract
Hospitals with Coronavirus disease (COVID-19) demand surges at the onset of the pandemic report medication
shortages, a worrisome phenomenon as inadequate medication supplies negatively affect patient outcomes.
The popular press implicates a lack of raw ingredients and spikes in purchases but rigorous research
is needed to more accurately identify shortage causes. We leverage a quasi-experimental design on IQVIA’s
National Sales Perspectives™ data from 2018-2020 with a focus on medicines related to U.S. hospital-based
COVID-19 treatment and a set of control medicines not used for COVID-19. We contribute to supply chain
theory by empirically demonstrating that stockpiling among U.S. medical providers in the early phase of the
pandemic accounts for the shortages. The buyers’ behavior results in concentration of the sales volume of
COVID-19 medicines in the first two months of the pandemic. After these first two months, the sales volume
of drugs for COVID-19 treatment decreases significantly despite a nationwide increase in COVID-19-related
hospitalizations. An implication for manufacturers is that orders due to stockpiling by downstream buyers
early on in a pandemic period should be discounted when predicting future demand. We also investigate
another potential cause: expected price increases in the future. Counter to concerns that drug manufacturers
would engage in price gouging behavior, we find no evidence of price inflation for these drugs. Our results are
robust to numerous sensitivity checks and have implications for manufacturers, hospitals, and policymakers
that may improve medicine supply resiliency against future threats.